Karina Savvulidi Vargova

Dr. Karina Savvulidi Vargova

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2011 in Blood
Verified
Journal Article
Closed access
PDF file
KVKarina Savvulidi Vargova
Karina Savvulidi Vargova
NCNikola Curik
Nikola Curik
PBPavel Burda
Pavel Burda
PBPetra Bašová
Petra Bašová
VKVojtech Kulvait
Vojtech Kulvait
TSTomas Stopka
Tomas Stopka
Elevated levels of microRNA miR-155 represent a candidate pathogenic factor in chronic B-lymphocytic leukemia (B-CLL). In this study, we present evidence that MYB (v-myb myeloblastosis viral oncogene homolog) is overexpressed in a subset of B-CLL patients. MYB physically associates with the promoter of miR-155 host gene (MIR155HG, also known as BIC, B-cell integration cluster) and stimulates its transcription. This coincides with the hypermethylated histone H3K4 residue and spread hyperacetylation of H3K9 at MIR155HG promoter. Our data provide evidence of oncogenic activities of MYB in B-CLL that include its stimulatory role in MIR155HG transcription.

6 September 2011 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
VPVit Pospisil
Vit Pospisil
KVKarina Savvulidi Vargova
Karina Savvulidi Vargova
JKJuraj Kokavec
Juraj Kokavec
JRJana Rybarova
Jana Rybarova
Filipp Georgijevic SavvulidiFilipp Georgijevic Savvulidi
Filipp Georgijevic Savvulidi
TSTomas Stopka
Tomas Stopka
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

12 June 2019 in Journal of Animal Science and Biotechnology
Verified
Journal Article
Open access
PDF file
Filipp Georgijevic SavvulidiFilipp Georgijevic Savvulidi
Filipp Georgijevic Savvulidi
Martin PtacekMartin Ptacek
Martin Ptacek
KVKarina Savvulidi Vargova
Karina Savvulidi Vargova
LSLuděk Stádník
Luděk Stádník
We are entering an exciting epoch in livestock biotechnology during which the fundamental approaches (such as transgenesis, spermatozoa cryopreservation and artificial insemination) will be enhanced based on the modern understanding of the biology of spermatogonial stem cells (SSCs) combined with the outstanding recent advances in genomic editing technologies and in vitro cell culture systems. The general aim of this review is to outline comprehensively the promising applications of SSC manipulation that could in the nearest future find practical application in livestock breeding. Here, we will focus on 1) the basics of mammalian SSC biology; 2) the approaches for SSC isolation and purification; 3) the available in vitro systems for the stable expansion of isolated SSCs; 4) a discussion of how the manipulation of SSCs can accelerate livestock transgenesis; 5) a thorough overview of the techniques of SSC transplantation in livestock species (including the preparation of recipients for SSC transplantation, the ultrasonographic-guided SSC transplantation technique in large farm animals, and the perspectives to improve further the SSC transplantation efficiency), and finally, 6) why SSC transplantation is valuable to extend the techniques of spermatozoa cryopreservation and/or artificial insemination. For situations where no reliable data have yet been obtained for a particular livestock species, we will rely on the data obtained from studies conducted in rodents because the knowledge gained from rodent research is translatable to livestock species to a great extent. On the other hand, we will draw special attention to situations where such translation is not possible.

11 August 2015 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
HHHana Huskova
Hana Huskova
KKKatarina Korecka
Katarina Korecka
JKJosef Karban
Josef Karban
JVJarmila Vargova
Jarmila Vargova
KVKarina Savvulidi Vargova
Karina Savvulidi Vargova
TSTomas Stopka
Tomas Stopka

11 January 2022 in Cells
Verified
Journal Article
Open access
PDF file
LMLubomir Minarik
Lubomir Minarik
KPKristýna Pimková
Kristýna Pimková
JKJuraj Kokavec
Juraj Kokavec
ASAdéla Schaffartziková
Adéla Schaffartziková
FVFrederic Vellieux
Frederic Vellieux
TSTomas Stopka
Tomas Stopka
The mechanisms by which myelodysplastic syndrome (MDS) cells resist the effects of hypomethylating agents (HMA) are currently the subject of intensive research. A better understanding of mechanisms by which the MDS cell becomes to tolerate HMA and progresses to acute myeloid leukemia (AML) requires the development of new cellular models. From MDS/AML cell lines we developed a model of 5-azacytidine (AZA) resistance whose stability was validated by a transplantation approach into immunocompromised mice. When investigating mRNA expression and DNA variants of the AZA resistant phenotype we observed deregulation of several cancer-related pathways including the phosphatidylinosito-3 kinase signaling. We have further shown that these pathways can be modulated by specific inhibitors that, while blocking the proliferation of AZA resistant cells, are unable to increase their sensitivity to AZA. Our data reveal a set of molecular mechanisms that can be targeted to expand therapeutic options during progression on AZA therapy.

6 December 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
KPKamila Polgarova
Kamila Polgarova
KVKarina Savvulidi Vargova
Karina Savvulidi Vargova
VKVojtech Kulvait
Vojtech Kulvait
NDNina Dusilkova
Nina Dusilkova
LMLubomir Minarik
Lubomir Minarik
TSTomas Stopka
Tomas Stopka
Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders